Combination immunotherapies with anti-VEGF antibody and tyrosine kinase inhibitors have achieved some encouraging results in clinical trials, which have included increased antigen presentation, increased activation and infiltration of CD8+ T cells, reduced expression of immunosuppressive components, and direct anti-tumor effects [25]. The gene discussed is CD8A; the disease is neoplasm.